1	Active case finding using mobile vans equipped with artificial intelligence aided
2	radiology tests and sputum collection for rapid diagnostic tests to reduce
3	tuberculosis prevalence in rural China: protocol for a pragmatic trial
4	
5	Xiaolin Wei ¹ ¶*, Dabin Liang ² ¶, Zhitong Zhang ¹ , Kevin Thorpe ¹ , Lingyun Zhou ² ,
6	Jinming Zhao ² , Huifang Qin ² , Xiaoyan Liang ² , Zhezhe Cui ² , Yan Huang ² ,
7	Liwen Huang ² , Mei Lin ^{2*}
8	
9	¹ Dalla Lana School of Public Health, University of Toronto, Toronto, ON,
10	Canada
11	² Guangxi Zhuang Autonomous Region Center for Disease Control and
12	Prevention; Guangxi Key Laboratory of Major Infectious Disease Prevention
13	and Control and Biosafety Emergency Response, Nanning, Guangxi Zhuang
14	Autonomous Region, China
15	
16	* Corresponding author
17	Email: xiaolin.wei@utoronto.ca (XW) and gxlinmei@126.com (ML)
18	
19	[¶] These authors contributed equally to this work.
20	
21	
22	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Abstract

24

25 Background

Tuberculosis (TB) remains a significant public health challenge, particularly in 26 27 rural areas of high-burden countries like China. Active case finding (ACF) and timely treatment has been proved effective in reducing TB prevalence but it is 28 still unknown regarding the impact on TB epidemic when employing new 29 technologies in ACF. This study aims to evaluate the effectiveness of a 30 comprehensive ACF package utilizing mobile vans equipped with artificial 31 intelligence (AI)-aided radiology, and GeneXpert testing in reducing TB 32 prevalence among high-risk populations in rural Guangxi, China. 33

34

35 Methods

A pragmatic cluster randomized controlled trial will be conducted in two 36 37 counties of Guangxi, China. The trial will randomize 23 townships to intervention or control groups at 1:1 ratio. The intervention group will receive a 38 single ACF campaign in Year 1, incorporating mobile vans, AI-based DR 39 screening, symptom assessment, and sputum collection for GeneXpert testing. 40 Control group participants will receive usual care. TB patients identified in Year 41 1 will be required to complete TB treatment in Year 2. The primary outcome is 42 the prevalence rate of bacteriologically confirmed TB among high-risk 43

44	populations in Year 3. Process evaluation will explore adaption, acceptability
45	and feasibility of the intervention. We will conduct incremental costing study to
46	inform future scale-up of the intervention in other settings.
47	
48	Discussion
49	This study will provide valuable insights into the effectiveness and feasibility of
50	utilizing AI, mobile vans and GeneXpert for TB ACF to reduce TB prevalence
51	in rural settings. If successful, this model will contribute to possible solutions to
52	achieve the WHO End TB Strategy by 2035.
53	
54	Trial registration: ClinicalTrials.gov Identifier -NCT06702774
55	
56	Keywords: Tuberculosis, active case finding, mobile van, artificial intelligence,
57	cluster randomized controlled trial, China
58	
59	
60	
61	
62	

63 Introduction

64

65	The United Nations passed the Resolution to end tuberculosis (TB) by 2035. TB
66	is the leading cause of death in infectious disease. In 2022, the world reported
67	7.5 million new TB cases and 1.3 million deaths caused by TB [1]. TB
68	incidence has declined by 2% a year between 2010 and 2020. However, the rate
69	has reverted to increase by 3.9% between 2020 and 2022 due to the COVID-19
70	pandemic [1]. To reach the END-TB resolution, global TB incidence has to be
71	reduced to less than 100 per million by 2035 [2]. The world is looking for
72	evidence of innovative approaches to eliminate TB in a relatively short time
73	frame [3].

74

The principle of "prevent, search, detect, treat" that has successfully reduced TB 75 prevalence in high-income countries in the last century [4]. Studies in high TB 76 burden countries also proved that active case finding (ACF) at the community 77 level would identify patients who are in their early stage of disease 78 development, or who may be delayed or missed in the routine passive case 79 finding at health facilities [4, 5]. A 2009 study in rural Zimbabwe showed both 80 mobile van and household-to-household sputum collection methods lowered TB 81 prevalence by 41% in three years, showing the potential of using mobile vans in 82 case finding [6]. Another study in rural Vietnam demonstrated that conducting 83

annual community screening based on a rapid molecular diagnostic tool
(GeneXpert) for three years could reduce 40% of TB prevalence in a high TB
burden setting [7]. However, GeneXpert costs around US\$15 per test, which is
prohibitive to be used as a large-scale screening tool.

88

More cost-effective active case-finding tools, such as computer-aided diagnostic 89 tools using artificial intelligence (AI) deep learning neural networks, have 90 shown satisfying sensitivity (86%) as a screening tool to reduce 66% of cases 91 needed for laboratory tests [8]. Operational studies revealed the feasibility and 92 effectiveness of using AI-facilitated X-ray and GeneXpert for community 93 screening and diagnosis [9]; however, most studies were pre-after comparisons 94 that were not properly designed to evaluate epidemiological impacts [10]. In 95 addition, two studies in Africa highlighted that the interventions were more 96 cost-effective when screening elders, close contacts with active TB patients, and 97 individuals with comorbidities such as diabetes and HIV [11, 12]. 98

99

Here, we aim to implement and evaluate the feasibility and effectiveness of a
comprehensive intervention package in rural Guangxi, China, a high TB
prevalent setting, that employs the latest technologies for active case finding to
reduce TB epidemics among high-risk populations. The technologies include
employing a mobile van equipped with AI aided radiology screening and
GeneXpert test for community active case finding in communities. Our study is

- 106 designed as a pragmatic clustered randomized controlled trial to evaluate the
- 107 effectiveness of the comprehensive package in reducing TB prevalence over a
- 108 period of three years among high-risk populations.
- 109
- 110 Methods
- 111
- 112 This protocol is reported according to the Standard Protocol Items:
- 113 Recommendations for Interventional Trials (SPIRIT) guidelines (see S1 Table).

114

115 Study status and timeline

116 The lifespan of this study will be 42 months in total, including 36 months for the main trial (Year 1-3). More details of trial timeline are included in the Fig 1. 117 The trial has been started since Nov 2021 and has been suspended for 3 months 118 due to COVID-19 control in Year 1, thus the progress was postponed 119 accordingly. Participant recruitment and data collection has been ongoing by the 120 time of submission of this protocol, which are estimated to be completed by end 121 of January 2025. The trial results will be disseminated through research articles 122 and policy briefs after the trial evaluation is completed after April 2025. We aim 123 to publish our results and findings in leading international medical journals and 124 present at national and international conferences. 125

126 Fig 1. SPIRIT schedule of enrolment.

127

128 Study design and setting

We will conduct a parallel two-group, cluster randomized controlled trial of a 129 comprehensive package of active case finding followed by timely treatment in 130 rural Guangxi China to evaluate whether the interventions could reduce the TB 131 epidemic compared to the usual care (Fig 2). Guangxi is located in southwest 132 China bordering with Vietnam. Guangxi reported 31,913 TB cases with 133 notification rate of 70/100,000 in 2020, representing the second highest TB 134 burden in China. Of the reported TB cases, 74% were from rural areas, and 30% 135 were elderly (\geq 65 years old). Mountainous areas in Guangxi had high TB 136 notification rates; for example, the two trial counties (Xincheng and Xiangzhou 137 of Laibin Prefecture) reported an average notification rate of 134/100,000, 138 which is two times the provincial average. In addition, the Covid-19 pandemic 139 has substantially delayed TB diagnosis and treatment, which would fuel up TB 140 transmission and exacerbate TB epidemic. 141

142 Fig 2. Trial design flow chart.

143

TB services in China is funded and delivered by the public health system at the
county, township and village levels. The TB free treatment policy requires basic
TB diagnosis tests and treatment should be free (for drug susceptible cases) or
supported by the health insurance schemes (for drug resistant cases). The
County Centre for Disease Control (CDC) is responsible for TB planning,

reporting and quality control, while TB clinical care is provided by the TB 149 Clinic at the County Hospital. Passive case finding is the practice of usual care, 150 where patients with chronic cough or other TB-related symptoms are self-151 presented or referred to the County Hospital for subsequent diagnosis and 152 treatment. TB diagnosis is based on sputum smear, chest X-ray examinations, 153 and clinical assessments. Standard WHO DOTS treatment regimen is provided 154 for patients diagnosed of drug-susceptible TB. TB patients visit the County 155 Hospital monthly for medication renewals. Patients take their anti-TB 156 medications on a daily basis with the support of village doctors, who are 157 community health workers. In Guangxi, village doctors are semi-private who 158 receive 50% of income from the township hospitals for their public health work 159 such as maternal and child health, immunization, pap smear screening, and 160 disease management including TB, diabetes, and hypertension, while they earn 161 the other 50% income from clinical consultations under the rural health 162 insurance scheme. According to the National TB Guideline, village doctors are 163 responsible to visit TB patients weekly. The public health doctor in the 164 township hospital is required to supervise village doctors and visit patients 165 monthly. However, the actual frequency is far less and often substituted via 166 phone calls. In each village, there is a female social worker in the Village 167 Committee, who plays a major role in public education, maternal and child care, 168 and protecting women's rights. These female social workers have a strong 169 connection with villagers but have not been involved in TB care. 170

171

172 Eligibility criteria

173 Clusters

174 We have two levels of clustering in this trial. Township is treated as the cluster

of intervention. A township is an administrative unit with a township hospital

and consists of 7-12 villages. All townships in Xincheng and Xiangzhou county,

which provide their willingness to participate, will be included. Villages within

the participating township serve as sub-cluster in the survey that determines the

179 TB prevalence rate.

180

181 **Participants**

In each township, all residents who are 15 or older become eligible and defined 182 as high-risk populations if they: 1) are elderly (i.e., aged 65 and above), or 2) 183 been aged below 65 but with one of the following conditions: being patients 184 previously treated for TB or close contacts of a patient with a TB patient 185 diagnosed within the last three years; having been clinically diagnosed with 186 diabetes, HIV positive, or worked as a miner. All eligible participants who 187 signed informed consent form will be recruited to the study. Residents who 188 refuse participation will be excluded. 189

190

191 **Procedures**

192 TB Care provided in both groups

193	Routine TB care is provided per the China National TB Guideline to both
194	groups, where passive case finding is practiced. Patients self-present or are
195	referred to the TB clinic at the County Hospital when they seek care for TB
196	related symptoms. TB diagnosis is based on X-ray examination, sputum smears
197	and clinical assessment. Confirmed TB patients are treated in County Hospitals
198	based on the WHO DOTS regiments for drug-sensitive TB. Those who are
199	diagnosed with multi-drug resistant (MDR) TB are referred to prefecture TB
200	designated hospital.
201	
202	Usual care
202 203	Usual care Usual care will be provided in the control group, and no active case finding
203	Usual care will be provided in the control group, and no active case finding
203 204	Usual care will be provided in the control group, and no active case finding
203 204 205	Usual care will be provided in the control group, and no active case finding activities will be provided.
203 204 205 206	Usual care will be provided in the control group, and no active case finding activities will be provided.
203 204 205 206 207	Usual care will be provided in the control group, and no active case finding activities will be provided. Intervention In the intervention group, in addition to usual care, we will implement one

- conduct door-to-door visits to recruit participants and obtain their informed
- consent. We will employ a mobile van equipped with the AI-facilitated digital
- radiography (DR) machine and refrigerator to visit villages on a mutually

agreed date. On the day, all eligible participants will be invited to complete a 214 brief questionnaire regarding TB related symptoms, and then invited to have 215 their DR examined in the van. Those who are presumptive of TB based on 216 either DR examination or any TB related symptoms, including any chronic 217 cough over two weeks, hemoptysis, fever, night sweats, chest pain or 218 unexplained weight loss, will be asked to produce a single on-site sputum. 219 These villagers are also asked to take two specimen boxes for collection of 220 night and morning sputum. All staff are trained for good quality sputum sample 221 collection, storage and transportation. Medical nebulizer inhalation will be 222 provided to those who can not provide good quality sputum. Sputum samples, 223 either collected on the day or delivered by village doctors within 48 hours, will 224 be stored in the refrigerator of the mobile van and transported to the county 225 hospitals at daily basis for sputum smear, culture and GeneXpert using sample 226 mixed approach which method of mixing is published elsewhere [13]. 227 Participants who are bacteriologically negative but have abnormal DR result or 228 229 TB symptoms will be referred to the county hospital for clinical assessment based on China National TB guideline. All diagnosed TB patients, either 230 bacteriologically or clinically confirmed, will be notified by the village doctor 231 within 48 hours and referred to the County Hospital for standard WHO DOTS 232 regiments per national guideline. 233

Fig 3. Algorithm of active TB case finding in intervention group.

a. TB symptoms include chronic cough over 2 weeks, hemoptysis, fever, night

sweats, chest pain or unexplained weight loss.

- 237 TB= tuberculosis, DR= digital radiography
- 238

Research activities apply to both groups:

240 We will wait for a year (cleaning period) to ensure all TB patients identified in

241 Year 1 complete the treatment. We will conduct epidemiological prevalence

survey in both groups in Year 3 using cluster-random sampling methods

adopted from WHO [14], targeting high-risk populations in both intervention

and control groups, to compare the TB prevalence rates. Regarding the survey,

we will apply the same active case finding activities as outlined above to both

intervention and control groups. For feasibility reasons, we plan to conduct the

survey in Year 3 at the village (sub-cluster) levels in both groups.

248

249 **Outcomes**

Our primary outcome indicator is the prevalence rate of bacteriologically positive TB in Year 3 among the high-risk populations, including those 65 and older, those who are under 65 but have a history of tuberculosis treatment or have been in close contact with a person diagnosed with TB within the past three years, have been clinically diagnosed with diabetes, HIV, or have a background of working as a miner. According to WHO definitions, bacteriologically positive case is defined as having a positive test from any of the three tests (i.e., GeneXpert, smear or culture). Prevalence is estimated using
a cluster-random survey among the high-risk populations that is conducted in
both the intervention and control groups in Year 3.

260

There is a list of secondary outcome indicators, which allow us to assess and 261 evaluate whether our interventions could bring positive impacts on TB epidemic 262 in the intervention and control groups: 1) prevalence rate of active TB, 263 including both bacteriologically positive and negative cases, among the high-264 risk populations in Year 3. This indicator will also rely on estimates from the 265 epidemiological survey in Year 3; 2) notification rates of bacteriologically 266 positive TB cases among all populations in Year 3; and 3) notification rates of 267 active TB cases, including both bacteriologically positive and negative cases 268 among all populations in Year 3. Nominators of the two notification rates will 269 include TB cases identified from our epidemiological survey in Year 3 plus TB 270 cases reported from the National TB Program, while both denominators include 271 all adult residents (i.e., those of 15 years and older) in the intervention and 272 control groups. 273

274

We will also collect costs from patient, health system and societal perspectives to conduct an incremental costing study. We will collect process indicators that will including a) the proportion of bacteriologically positive cases identified by active case finding in the intervention group; b) the yield rate of our

intervention, which is the number of bacteriologically positive cases per 100persons screened using each strategy.

281

282 Sample size

283 The sample size is calculated for the investigation of the primary outcome, i.e,

the prevalence rate of bacteriologically confirmed TB, that will be conducted in

Year 3. We estimated that the TB prevalence rate among the high-risk

populations in the trial area is about 300 per 100,000. We assume our

intervention will reduce the rate among the high-risk populations in the

intervention group by 50% (i.e., to 150 per 100,000) within 24 months, which

can be considered as a significant reduction at the population level. We estimate

that the intra-class correlation coefficient for TB prevalence was 0.001 [7]. The

average number of eligible participants is about 500 per village based on the

initial reports. We estimate that we would need 47 villages (that is,

approximately 23,500 participants) in each group to have 80% power to detect

the reduction estimated above, assuming p < 0.05.

295

296 Recruitment, randomization and blinding

There are 23 townships and 255 villages in Xincheng and Xiangzhou county of Laibin city [15]. We will implement the active case finding intervention at the township level to avoid contamination because township hospitals manage

village doctors. We seek to recruit all willing townships. After recruitment, the 300 study statistician will use a custom-written computer program to randomize all 301 recruited townships, stratified by county, assigning them to the control and 302 intervention group in an overall 1:1 ratio (12 intervention vs 11 control) [16]. 303 Then township/village doctors and county hospital staff in the intervention 304 group will be invited to receive training about specific interventions in this 305 project. For the epidemiological survey in Year 3, the statistician will randomly 306 select 47 villages (sub-clusters) from each group stratified by county. We will 307 seek written informed consent from each participant before enrollment, as we 308 need to collect their health information, bio-sample (sputum) and test result for 309 research purpose. 310

311

Due to the nature of the intervention, neither single nor double blindness
procedure is applicable. However, we will blind the data analysts who process
the end-point data for outcome assessment.

315

316 **Data collection**

We will collect all types of field data produced during the trial, including
patients' basic information, disease history, health information, DR test result,
laboratory test result for TB and diagnosis, as well as routine TB reporting data.
All data will be entered into a data website designed for this project, accessible
only by designated researchers via local intranet with a password. Individual

data will be deidentified and stored for five years after the completion of the
trial. For research purpose, we will define all outcomes at the subcluster-level
and will calculate them from the individual-level data as single summary
outcome values, such as prevalence per cluster.

326

327 Active screening

328 During the active case screening, we will collect the information about

suspicious symptoms, including chronic cough for more than 2 weeks,

hemoptysis, blood sputum, fever, night sweats, chest pain or unexplained

331 weight loss, and TB risk factors (close contact history of tuberculosis patients,

diabetes, AIDS/HIV and dust exposure).

333

334 Laboratory testing and clinical consultation

The county hospitals will carry out laboratory testing according to the 'TB 335 Laboratory Testing Protocol'. Sputum smear test, GeneXpert test and sputum 336 culture are carried out at the same time. Every five samples of sputum are mixed 337 for GeneXpert test to save costs. Those positive mixed sample will be tested 338 separately to confirm the positive case. Country hospitals will distribute the 339 340 laboratory testing results to patients within 48 hours. All TB diagnoses will be recorded in the 'Register of Newly Diagnosed Patients' (labelled with subject 341 number) in detail. Clinical diagnosis based on the clinical assessment is 342 performed by doctors in county hospitals according to the national TB 343

Classification Criteria (WS196-2017) and Diagnostic Criteria (WS288-2017)
[17, 18]. We will also collect TB cases diagnosed through the usual care in both
intervention and control groups through the three years.

347

348 **Primary and secondary outcomes**

The data collection approach in Year 3 for the outcome evaluation will be the 349 same as the active TB case finding in the intervention group in Year 1. As we 350 define most of our outcomes as single summary values at the subcluster-level, 351 such as prevalence and incidence, we will sample from both intervention and 352 control group, calculate and compare the outcomes following the trial period. 353 Take the primary outcome, the prevalence of bacteriologically positive TB, for 354 instance, we will sample all high-risk populations of selected villages (sub-355 clusters) of the two groups, conduct a sputum smear, GeneXpert, sputum culture 356 test, and compare the calculated prevalence of bacteriologically positive TB. A 357 similar process also applies to measure secondary outcomes, such as prevalence 358 359 of active TB in two groups.

360

361 Statistical analysis

The results of this project will be reported according to the 'Consolidated Standards of Reporting Trials: Extension for Cluster Trials' (CONSORT) guidelines [19]. We will create a detailed statistical analysis plan. In the full research paper, we will present appropriate descriptive statistics for the two

366	counties and all relevant participants before and during the trial. In addition,
367	using cluster-level methods of analysis, we can get a main set of estimates for
368	our primary and secondary outcomes after the trial, acting as the primary
369	evidence for determining the effectiveness of this trial. Appropriate summary
370	statistics and their associated 95% confidence interval for all differences
371	outcomes between the intervention group and the control group will be
372	calculated. No interim analyses are involved in this project.
373	
374	For the primary outcome and all secondary proportion-based outcomes, the
375	statistical analysis will employ a mixed-effect logistic regression model
376	including random effects for township and village. The intervention effect will
377	be expressed as an odds ratio with 95% confidence intervals. Secondary
378	analyses of these outcomes will adjust for the following variables: age, sex, and
379	ethnicity.
380	

For continuous secondary outcomes we will employ a linear mixed-effect model with random effects for township and village. This model will also adjust for the following variables: age, sex, and ethnicity. The intervention effect will be expressed as the adjusted mean difference with 95% confidence intervals.

386 Process evaluation

Since our project contains multiple components, the process evaluation during 387 and after the trial is guided by the framework for design and evaluation of 388 complex interventions [20, 21]. Utilizing a combination of qualitative and 389 quantitative methods, process evaluation for the complex interventions in our 390 cRCT can explore the mechanism of achieving the intervention effects [22]. In 391 other words, we can get insights of a series questions such as 'what 392 interventions are effective in which policies and implementation environments, 393 for whom and why?'. We will conduct around 30 in-depth semi-structured 394 interviews with leading personnel at all levels of health agencies, township and 395 village doctors, county hospital staffs, social workers, and trial participants in 396 the intervention group. 397

398

Our specific objectives for the process evaluation include: 1) to determine 399 intervention accessibility by the number of subjects receiving screening, 400 presented to county hospitals, and under treatment, as well as their feedbacks; 2) 401 to explore the intervention effectiveness (reasons for both effectiveness and 402 ineffectiveness), along with the relationship between interventions and expected 403 results; 3) to access the acceptance of intervention implementation at the 404 organization level and the staff level – any conflicts with existing management 405 or policies, and corresponding adjustment; 4) to report intervention fidelity, the 406 degree and quality of intervention completion, as well as challenges and 407 unexpected results, at both subcluster-level and individual level. 408

409

410 Analysis of process evaluation

411 All the recorded interviews will be transcribed and translated into English

412 before qualitative analysis. We will use NVivo 10 software to process and

analyze our qualitative data guided by a framework analysis as described by

414 Gale at al [23], to identify themes related to our process evaluation objectives.

415 The findings will be reported based on the Consolidated Criteria for Reporting

416 Qualitative Research (COREQ) guidelines [24].

417

418 Costing study

This study will measure the incremental cost-effectiveness of interventions 419 compared with conventional TB finding, using research data and literature to 420 evaluate both health system and social benefits. We will compare direct costs 421 and outcomes of the intervention group to those of the control group throughout 422 the 24-month trial. The objective of the costing study is to calculate the 423 incremental cost-effectiveness ratio (the increased costs required for each 1% 424 reduction in the prevalence of active TB among high-risk populations) using 425 data from the project's primary outcome. 426

427

428 Data collection

We will send out a questionnaire to directors of all recruited township or villagehospitals to collect health care resources used in the trial, along with their costs.

The data include: 1) average salaries, in RMB, for each level of staff in 431 designed hospitals who participated in this project; 2) average salaries, in RMB, 432 for township and village doctors who do not work in designated hospitals but 433 still participated in the project; 3) average salaries, in RMB, for social workers 434 and other personnel worked in the project implementation; 4) the duration of 435 consultations on mobile health vehicle and in county hospital); 5) the frequency 436 and duration of staff training and sequential meetings during the process; 7) cost 437 for TB screening (i.e. symptom screening, chest DR, mobile van operation, 438 sending samples to county hospitals) and laboratory test (e.g. sputum smear, 439 culture, and GeneXpert). To optimize the data quality, we will double-entry and 440 random-check the input data. 441

442

443 Estimation of resources use and costs

Healthcare resources in this case include resources used for TB detection and
diagnosis. The cost per patient is calculated as the sum of consultation,
screening and laboratory testing. The total costs is calculated for the main
analysis population as described in the Statistical Analysis section [25].

449 Estimation of implementation costs

The implementation costs are calculated separately and will not be accounted in
the cost-effectiveness analysis. The objective of this estimation is to inform
policy makers and stakeholder of the potential cost to facilitate their decision on

whether to implement the intervention at scale. For each cluster, the
implementation costs included the cost of training for personnel, the cost of
personnel to attend training, the costs for developing and printing the handbook
or guidelines per training attendee, operation cost of mobile van, driver cost,
setup cost of AI facilitated DR, the costs for producing symptom questionnaires
used in the project, and the costs of sending samples back to county hospitals.

460 Trial management

Guangxi CDC will lead this project and have full access to all the anonymized 461 data and information associated with the trial. We will establish a data 462 monitoring committee (DMC) to ensure all data are collected in conformity 463 with the agreed ethical guidelines, stored in Guangxi CDC properly and used 464 for research purposes only. Meanwhile, the DMC is also responsible for the 465 safety and privacy protection of all the subjects and providers participated in the 466 trial. Additionally, there will be a trial steering committee (TSC) lead by 467 external members to generate the progress of the trial. We will hold regular 468 online meetings with both DMC and TSC every 6 months to get updates and 469 discuss any protocol modifications, starting from the beginning of the study, 470 until it completes. If there are any changes or concerns needed to report or 471 discuss, the committees can meet on an ad hoc basis with the co-leaders as well. 472 Moreover, a trial management unit (TMU) will be established in consisting of 473

three local staff. The responsibility of the TMU is to better manage the day-to-day activities of the trial according to the study protocol.

476

477 **Discussion**

478 This study aims to enhance the existing TB control protocol in an area of high TB prevalence. As the location of implementation, Laibin is an ethnically 479 diverse area with the highest reported TB incidence rate in Guangxi region. In 480 other words, it has an urgent need to find a more effective way to manage its TB 481 epidemic. Given that about 27% of all reposted cases in Guangxi region are 482 from the elderly population, the interventions target the elderly and also pay 483 special attention to other populations who have high risk of TB infection [15, 484 26, 27]. 485

486

The study has significant policy relevance to China and globally. The objective 487 488 of this study is to effectively reduce the TB epidemic in Guangxi and achieve the WHO's End TB Strategy [2] milestones by 2024. If successful, the 489 prevalence of TB in the intervention areas will be reduced by more than 50%. It 490 aligns with the goal to build a healthy China as well. The successful 491 implementation of this study will yield a feasible TB control strategy that can be 492 replicated in other parts of China, which may provide a model for countries with 493 similar context to achieve to the WHO's goal to end TB by 2035 [2]. 494

495

496	Furthermore, active screening interventions involve innovative technologies.
497	Since over 40% of areas in Laibin are mountainous, the mobile health vehicles
498	equipped with DR machines and refrigerators make active screening procedures
499	more convenient, and all the bio-samples can be properly stored and timely
500	transported to the county hospital. In addition, the AI-based diagnostic system
501	(above 90% sensitivity) offers axillary support to detect abnormalities in DR
502	images, increasing the test efficacy [28].
503	
504	Nevertheless, there are some limitations in this study as well. First, TB-
505	suspected participants in the active screening intervention are required to collect
506	two sputum samples (one for morning and one for night sputum) and send them

507 to village doctors. Although specific equipment and instructions will be given,

there are still risks of improper sample collection or transportation, which may

509 affect laboratory results and TB diagnosis. We provide training for people

assumptive of TB in sputum collection to improve the quality. Secondly, due to

511 the limitation of funding and human resources, we are not able to conduct active

case finding among all populations in participating townships in Year 3.

513 Therefore, the trial cannot evaluate the impact of interventions on TB

- 514 prevalence in the general population. On the other side, a survey of the
- 515 population may not be feasible anyway because most people of working ages in
- ⁵¹⁶ rural areas moved to urban areas as migrants during most time of the year, while

- only elders, who comprise the majority of our high-risk population, and children
- stay at home. Our active case-finding activity targeting high-risk populations
- 519 would significantly reduce TB in rural areas.
- 520

521 List of abbreviations

- 522 AI: Artificial Intelligence
- 523 AIDS: Acquired Immunodeficiency Syndrome
- 524 CDC: Center for Disease Prevention and Control
- 525 DMC: Data Monitoring Committee
- 526 DR: Digital Radiography
- 527 HIV: Human immunodeficiency Virus
- 528 MDR-TB: Multidrug-resistant Tuberculosis
- 529 NTP: National TB Program
- 530 RCT/cRCT: Randomised Controlled Trial/Cluster Randomised Controlled Trial
- 531 TB: Tuberculosis
- 532 TCS: Trial Steering Committee
- 533 TMU: Trial Management Unit
- 534 WHO: World Health Organization

535

536 Acknowledgement

537	We acknowledge Guangxi Laibin Prefectural Center for Disease Control and
538	Prevention, Xincheng and Xiangzhou County Centers for Disease Control and
539	Prevention as well as all the health providers and patients who participate in
540	discussions to develop the proposal.
541	

542 Data sharing statement

543 Metadata won't be publicly available due to local policy. Clustered data can be

shared by email (Guangxi CDC, lxy530028@163.com) based on reasonable

request for research purpose only upon approval after January 1, 2027.

546

547 **Competing interests statement**

548 The authors declared no competing interests.

549

550 Ethical approvals and consent to participate

551 The study has obtained ethical approval from the Guangxi Institutional Review

552 Board of the Guangxi CDC on 26 August 2021 (Ref: GXIRB2021-0033).

553 Written informed consent form will be collected before any patient is recruited

554 into the study.

555

556 **Reference**

557 1. WHO. Global tuberculosis report 2023. Geneva: the World Health Organization,,

558 2023.

- 559 2. World Health Organization [WHO]. The End TB Strategy2015 [cited 2022 Feb. 19];
- 560 2022(Feb. 19). Available from: https://www.who.int/teams/global-tuberculosis-
- 561 programme/the-end-tb-strategy.
- 562 3. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al.
- 563 Tuberculosis control and elimination 2010–50: cure, care, and social development. The

564 Lancet. 2010;375(9728):1814-29. doi: <u>https://doi.org/10.1016/S0140-6736(10)60483-7</u>.

- 565 4. WHO. Systematic screening for active tuberculosis: Principles and
- 566 Recommendations. Geneva: World Health Organization; 2013.
- 567 5. Kranzer K, Afnan-Holmes H, Tomlin K, Golub JE, Shapiro AE, Schaap A, et al. The
- 568 benefits to communities and individuals of screening for active tuberculosis disease: a
- 569 systematic review. Int J Tuberc Lung Dis. 2013;17(4):432-46. Epub 2013/03/15. doi:
- 570 10.5588/ijtld.12.0743. PubMed PMID: 23485377.

571 6. Corbett EL, Bandason T, Duong T, Dauya E, Makamure B, Churchyard GJ, et al.

572 Comparison of two active case-finding strategies for community-based diagnosis of

573 symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare,

- 574 Zimbabwe (DETECTB): a cluster-randomised trial. Lancet. 2010;376(9748):1244-53. Epub
- 575 2010/10/07. doi: 10.1016/s0140-6736(10)61425-0. PubMed PMID: 20923715; PubMed
- 576 Central PMCID: PMC2956882.

577 7. Marks GB, Nguyen NV, Nguyen PTB, Nguyen TA, Nguyen HB, Tran KH, et al.

578 Community-wide Screening for Tuberculosis in a High-Prevalence Setting. N Engl J Med.

579 2019;381(14):1347-57. Epub 2019/10/03. doi: 10.1056/NEJMoa1902129. PubMed PMID:

580 31577876.

581 8. Qin ZZ, Sander MS, Rai B, Titahong CN, Sudrungrot S, Laah SN, et al. Using artificial 582 intelligence to read chest radiographs for tuberculosis detection: A multi-site evaluation of 583 the diagnostic accuracy of three deep learning systems. Sci Rep. 2019;9(1):15000. Epub 584 2019/10/20. doi: 10.1038/s41598-019-51503-3. PubMed PMID: 31628424; PubMed Central 585 PMCID: PMCPMC6802077. 586 9. Zaidi SMA, Habib SS, Van Ginneken B, Ferrand RA, Creswell J, Khowaja S, et al. 587 Evaluation of the diagnostic accuracy of Computer-Aided Detection of tuberculosis on Chest 588 radiography among private sector patients in Pakistan. Sci Rep. 2018;8(1):12339. Epub 589 2018/08/19. doi: 10.1038/s41598-018-30810-1. PubMed PMID: 30120345; PubMed Central 590 PMCID: PMCPMC6098114. 591 Pande T, Cohen C, Pai M, Ahmad Khan F. Computer-aided detection of pulmonary 10. 592 tuberculosis on digital chest radiographs: a systematic review. Int J Tuberc Lung Dis. 593 2016;20(9):1226-30. Epub 2016/08/12. doi: 10.5588/ijtld.15.0926. PubMed PMID: 594 27510250. 595 Kranzer K, Lawn SD, Meyer-Rath G, Vassall A, Raditlhalo E, Govindasamy D, et al. 11. 596 Feasibility, Yield, and Cost of Active Tuberculosis Case Finding Linked to a Mobile HIV Service 597 in Cape Town, South Africa: A Cross-sectional Study. PLOS Medicine. 2012;9(8):e1001281. 598 doi: 10.1371/journal.pmed.1001281. 599 12. Sekandi JN, Dobbin K, Oloya J, Okwera A, Whalen CC, Corso PS. Cost-effectiveness 600 analysis of community active case finding and household contact investigation for 601 tuberculosis case detection in urban Africa. PLoS One. 2015;10(2):e0117009-e. doi: 602 10.1371/journal.pone.0117009. PubMed PMID: 25658592. 603 Qin H, Liang X, Zhou L, Lan Y, Lin M, Zhang Z, et al. Analysis on the effect of 13. 604 GeneXpert MTB/RIF single test and mixed test on sputum samples for actively screening

tuberculosis in key population of Guangxi. Chinese Journal of Antituberculosis.

606 2023;45(9):880-4.

607 14. Bennett S, Woods T, Liyanage WM, Smith DL. A simplified general method for

608 cluster-sample surveys of health in developing countries. World Health Stat Q.

609 1991;44(3):98-106. PubMed PMID: 1949887.

610 15. National Bureau of Statistics. The seventh national population census. 2021.

611 16. Hothorn T, Everitt BS. A Handbook of Statistical Analyses Using R. 1st ed. ed. New

612 York: Chapman and Hall/CRC; 2006.

613 17. National Health and Family Planning Commission of China. Classification of

614 tuberculosis. 2017.

18. National Health and Family Planning Commission of China. Diagnosis for pulmonarytuberculosis. 2017.

617 19. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement:

618 extension to cluster randomised trials. BMJ : British Medical Journal. 2012;345:e5661. doi:

619 10.1136/bmj.e5661.

620 20. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, et

al. Framework for design and evaluation of complex interventions to improve health. BMJ.

622 2000;321(7262):694-6. doi: 10.1136/bmj.321.7262.694. PubMed PMID: 10987780.

623 21. Grant A, Treweek S, Dreischulte T, Foy R, Guthrie B. Process evaluations for cluster-

randomised trials of complex interventions: a proposed framework for design and reporting.

625 Trials. 2013;14(1):15. doi: 10.1186/1745-6215-14-15.

626 22. Oakley A, Strange V, Bonell C, Allen E, Stephenson J, Team RS. Process evaluation in

627 randomised controlled trials of complex interventions. BMJ. 2006;332(7538):413-6. doi:

628 10.1136/bmj.332.7538.413. PubMed PMID: 16484270.

629	23	Gale NK Heath G	Cameron F	Rashid S	Redwood S	Using the	framework method
029	Z J.	Uale INK, Heath U	, Cameron L	, Nasinu J	, neuwoou 5 .	Using the	II alliework method

- 630 for the analysis of qualitative data in multi-disciplinary health research. BMC Medical
- 631 Research Methodology. 2013;13(1):117. doi: 10.1186/1471-2288-13-117.
- 632 24. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research
- 633 (COREQ): a 32-item checklist for interviews and focus groups. International Journal for

634 Quality in Health Care. 2007;19(6):349-57. doi: 10.1093/intqhc/mzm042.

- 635 25. Hayes RJ, Moulton LH. Cluster Randomised Trials. 2nd ed. ed: Chapman and
- 636 Hall/CRC; 2017.
- 637 26. Zhang C, Wang L-x, Zhang H, Cheng J. Cost-effective study of different strategies for
- 638 pulmonary tuberculosis case finding in elderly people. Chinese Journal of Antituberculosis.
- 639 2013;35(10):794-8.
- 640 27. Technical Guidance Group of the Fifth National TB Epidemiological Survey, The Office
- of the Fifth National TB Epidemiological Survey. The fifth national tuberculosis
- epidemiological survey in 2010. Chinese Journal of Antituberculosis. 2012;34(8):485-508.
- 643 28. Qin ZZ, Ahmed S, Sarker MS, Paul K, Adel ASS, Naheyan T, et al. Tuberculosis
- 644 detection from chest x-rays for triaging in a high tuberculosis-burden setting: an evaluation
- of five artificial intelligence algorithms. Lancet Digit Health. 2021;3(9):e543-e54. doi:
- 646 10.1016/s2589-7500(21)00116-3. PubMed PMID: 34446265.

647

648 Supporting information

649 S1 Table SPIRIT checklist

	STUDY PERIOD				
Year		1	2	3	
Month	1-3	4-15	16-27	28-39	40-42
Preparation					
Study design					
Research tools development					
Interventions					
Enrollment					
Intervention					
Control					
Cleaning Period					
Evaluation					
Epidemiological survey					
Trial data collection					
Process evaluation					
Economic evaluation					
Data analysis and result dissemination					

Fig 1




Fig 2




Fig 3